← Back to Clinical Trials
Recruiting NCT06438432

NCT06438432 Trunk Activity Rehabilitation in Young Children With Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06438432
Status Recruiting
Phase
Sponsor Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
Condition Children With Cerebral Palsy
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2024-04-25
Primary Completion 2026-10-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Months
Max Age 6 Years
Study Type INTERVENTIONAL
Interventions
RAIT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2024-04-25 with a primary completion date of 2026-10-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Children with CP exhibit trunk control issues from early childhood, affecting their balance and gait. These issues manifest as unstable walking, increased step width, and more pronounced anterior deceleration of the sternum. Previous studies have shown that early action of the triceps surae compensates for the deficit in trunk postural control. Rehabilitation targeting the trunk has shown significant improvements in postural control and gait. The main objective is to demonstrate that RAIT (Rehabilitation by Activities Involving the Trunk) significantly reduces the peak anterior deceleration of the sternum at the beginning of the stance phase during barefoot spontaneous walking, with an enhanced effect from prolonged RAIT duration. Secondary objectives include reducing the downward deceleration of the fifth lumbar vertebra (L5), step width, gait variability index, and improving scores on the early clinical balance scale and the global motor function evaluation. Participants, children with spastic paraparesis or spastic hemiparesis capable of walking independently, are divided into two groups: one group continuing their usual rehabilitation for 3 months followed by RAIT for 9 months (RH-RAIT), and one group following RAIT for 12 months (RAIT-RAIT). RH involves rehabilitation exercises for lower limb muscles, while RAIT focuses on improving trunk postural control through activities involving intermediate postures. Functional motor assessments will be conducted initially, then at 3, 6, and 12 months. These include clinical evaluations, gait analysis (step width, gait variability index, anterior foot support), and an analysis of static standing displacement using an inertial sensor placed at L5. At M0, children with CP are expected to show higher values for deceleration peaks and gait variability indices, and lower scores on evaluation scales compared to typically developing (TD) children. After RAIT, an improvement in judgment criteria is expected: reduction in deceleration peaks, cycle width, gait variability index, anterior foot support, and an increase in scores on the ECPE and EMFG-66-SI. This study aims to confirm that rehabilitation through trunk-involving activities is more effective than usual rehabilitation in improving postural control and gait dynamics in young children with cerebral palsy, suggesting that this approach could become a standard rehabilitation practice from early childhood.

Eligibility Criteria

Inclusion Criteria: For children with CP * Age between 18 months and 5 years 6 months * CP type: spastic paraparesis or spastic hemiparesis, GMFCS I to II * No or moderate retraction of the sural triceps (ankle dorsiflexion: \> 5° on clinical examination, knee straight) * Sufficient level of understanding to carry out activities involving the trunk in the form of self-exercises (rehabilitation protocol), as well as clinical assessments and functional explorations. * Acceptance by the physiotherapist in charge of the child's follow-up to collaborate in carrying out the RAIT. * Affiliated with a social security scheme For children with DT * Age between 18 months and 5 years 6 months * Walking acquired before age 18 months * Sufficient level of understanding to perform clinical assessments and functional explorations * Affiliated with a social security scheme Exclusion Criteria: For children with CP * Previous surgery on lower limbs less than 1 year ago * Botulinum toxin A injection less than 6 months ago * Any change in rehabilitative and/or orthopedic management in the last 2 months * Hip flessum \> 20 * Presence of subacute or chronic pain on standing or walking For children with DT \- Neurological and/or orthopedic disorders that may influence gait

Contact & Investigator

Central Contact

Jonathan Pierret, PhD

✉ jonathan.pierret@ugecam.assurance-maladie.fr

📞 +33 3 83 52 6761

Frequently Asked Questions

Who can join the NCT06438432 clinical trial?

This trial is open to participants of all sexes, aged 18 Months or older, up to 6 Years, studying Children With Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06438432 currently recruiting?

Yes, NCT06438432 is actively recruiting participants. Contact the research team at jonathan.pierret@ugecam.assurance-maladie.fr for enrollment information.

Where is the NCT06438432 trial being conducted?

This trial is being conducted at Nancy, France.

Who is sponsoring the NCT06438432 clinical trial?

NCT06438432 is sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est. The trial plans to enroll 32 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology